Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 29Active not recruiting 13Terminated 10Withdrawn 3Recruiting 3Approved for marketing 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 27INDUSTRY 3NETWORK 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Other solid neoplasm 1Breast 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 241Carboplatin 170Injections 139Paclitaxel 122Gemcitabine 118Bevacizumab 117Cisplatin 108Pemetrexed 80Docetaxel 80Cyclophosphamide 74Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 60Nivolumab 55Cetuximab 53fludarabine 52Leucovorin 51130-nm albumin-bound paclitaxel 50Dexamethasone 46Rituximab 41atezolizumab 38venetoclax 35toripalimab 35Drug Therapy 35enzalutamide 32Prednisone 32Letrozole 32Irinotecan 32durvalumab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × niraparib × Clear all
NCT06915025 2026-05-04

OVATION-3

Imunon

Phase 3 Recruiting
500 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

GlaxoSmithKline

Phase 2 Recruiting
30 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

LaNova Medicines Limited

Phase 1/2 Recruiting
320 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡